{"id":2680,"date":"2016-10-07T10:50:00","date_gmt":"2016-10-07T10:50:00","guid":{"rendered":"https:\/\/bxt-accelyon.com\/?p=2680"},"modified":"2021-09-14T21:34:46","modified_gmt":"2021-09-14T21:34:46","slug":"brachytherapy-alone-for-intermediate-risk-prostate-cancer","status":"publish","type":"post","link":"https:\/\/bxta.com\/pt\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/","title":{"rendered":"Brachytherapy alone for intermediate-risk prostate cancer"},"content":{"rendered":"
\n

A new study has found that men with intermediate-risk prostate cancer can be safely and effectively treated with radioactive-seed brachytherapy alone without needing additional external-beam radiation. The finding represents a paradigm shift, say the researchers, and an outside expert agrees.<\/p>\n\n\n\n

Read more about the study<\/a><\/p>\n<\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":10,"featured_media":2642,"comment_status":"open","ping_status":"open","sticky":false,"template":"template-old-blog.php","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[10],"tags":[],"class_list":["post-2680","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-patients"],"acf":[],"yoast_head":"\nBrachytherapy alone for intermediate-risk prostate cancer - BXTA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bxta.com\/pt\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Brachytherapy alone for intermediate-risk prostate cancer - BXTA\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bxta.com\/pt\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"BXTA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/bxtainternational\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-10-07T10:50:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-14T21:34:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bxta.com\/wp-content\/uploads\/2021\/05\/Screenshot-2021-05-06-at-16.38.44.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1106\" \/>\n\t<meta property=\"og:image:height\" content=\"736\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Marketing BXTA\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BXTA_\" \/>\n<meta name=\"twitter:site\" content=\"@BXTA_\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marketing BXTA\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bxta.com\\\/fr\\\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/fr\\\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\\\/\"},\"author\":{\"name\":\"Marketing BXTA\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#\\\/schema\\\/person\\\/be7f4368cd4f7e11918870d00223473a\"},\"headline\":\"Brachytherapy alone for intermediate-risk prostate cancer\",\"datePublished\":\"2016-10-07T10:50:00+00:00\",\"dateModified\":\"2021-09-14T21:34:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/fr\\\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\\\/\"},\"wordCount\":51,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/fr\\\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bxta.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Screenshot-2021-05-06-at-16.38.44.png\",\"articleSection\":[\"Patient\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bxta.com\\\/fr\\\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\\\/\",\"url\":\"https:\\\/\\\/bxta.com\\\/fr\\\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\\\/\",\"name\":\"Brachytherapy alone for intermediate-risk prostate cancer - BXTA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/fr\\\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/fr\\\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bxta.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Screenshot-2021-05-06-at-16.38.44.png\",\"datePublished\":\"2016-10-07T10:50:00+00:00\",\"dateModified\":\"2021-09-14T21:34:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/fr\\\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\\\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bxta.com\\\/fr\\\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/bxta.com\\\/fr\\\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/bxta.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Screenshot-2021-05-06-at-16.38.44.png\",\"contentUrl\":\"https:\\\/\\\/bxta.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Screenshot-2021-05-06-at-16.38.44.png\",\"width\":1106,\"height\":736},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bxta.com\\\/fr\\\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/bxta.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brachytherapy alone for intermediate-risk prostate cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#website\",\"url\":\"https:\\\/\\\/bxta.com\\\/uk\\\/\",\"name\":\"BXTA\",\"description\":\"Let\u2019s tackle Prostate Cancer together | BXTA\",\"publisher\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bxta.com\\\/uk\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#organization\",\"name\":\"BXTA\",\"url\":\"https:\\\/\\\/bxta.com\\\/uk\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/bxta-staging.s3.eu-west-2.amazonaws.com\\\/app\\\/uploads\\\/2021\\\/09\\\/07212056\\\/BXTA-Logo.png\",\"contentUrl\":\"https:\\\/\\\/bxta-staging.s3.eu-west-2.amazonaws.com\\\/app\\\/uploads\\\/2021\\\/09\\\/07212056\\\/BXTA-Logo.png\",\"width\":600,\"height\":373,\"caption\":\"BXTA\"},\"image\":{\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/bxtainternational\\\/\",\"https:\\\/\\\/x.com\\\/BXTA_\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/bxtaccelyon\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCkTU9L10CS5c1eWtGiMZ7gw\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bxta.com\\\/uk\\\/#\\\/schema\\\/person\\\/be7f4368cd4f7e11918870d00223473a\",\"name\":\"Marketing BXTA\",\"url\":\"https:\\\/\\\/bxta.com\\\/pt\\\/author\\\/marketingbxta\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Brachytherapy alone for intermediate-risk prostate cancer - BXTA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bxta.com\/pt\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/","og_locale":"pt_PT","og_type":"article","og_title":"Brachytherapy alone for intermediate-risk prostate cancer - BXTA","og_url":"https:\/\/bxta.com\/pt\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/","og_site_name":"BXTA","article_publisher":"https:\/\/www.facebook.com\/bxtainternational\/","article_published_time":"2016-10-07T10:50:00+00:00","article_modified_time":"2021-09-14T21:34:46+00:00","og_image":[{"width":1106,"height":736,"url":"https:\/\/bxta.com\/wp-content\/uploads\/2021\/05\/Screenshot-2021-05-06-at-16.38.44.png","type":"image\/png"}],"author":"Marketing BXTA","twitter_card":"summary_large_image","twitter_creator":"@BXTA_","twitter_site":"@BXTA_","twitter_misc":{"Escrito por":"Marketing BXTA","Tempo estimado de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bxta.com\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/#article","isPartOf":{"@id":"https:\/\/bxta.com\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/"},"author":{"name":"Marketing BXTA","@id":"https:\/\/bxta.com\/uk\/#\/schema\/person\/be7f4368cd4f7e11918870d00223473a"},"headline":"Brachytherapy alone for intermediate-risk prostate cancer","datePublished":"2016-10-07T10:50:00+00:00","dateModified":"2021-09-14T21:34:46+00:00","mainEntityOfPage":{"@id":"https:\/\/bxta.com\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/"},"wordCount":51,"commentCount":0,"publisher":{"@id":"https:\/\/bxta.com\/uk\/#organization"},"image":{"@id":"https:\/\/bxta.com\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/bxta.com\/wp-content\/uploads\/2021\/05\/Screenshot-2021-05-06-at-16.38.44.png","articleSection":["Patient"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/bxta.com\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/","url":"https:\/\/bxta.com\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/","name":"Brachytherapy alone for intermediate-risk prostate cancer - BXTA","isPartOf":{"@id":"https:\/\/bxta.com\/uk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bxta.com\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/#primaryimage"},"image":{"@id":"https:\/\/bxta.com\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/bxta.com\/wp-content\/uploads\/2021\/05\/Screenshot-2021-05-06-at-16.38.44.png","datePublished":"2016-10-07T10:50:00+00:00","dateModified":"2021-09-14T21:34:46+00:00","breadcrumb":{"@id":"https:\/\/bxta.com\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bxta.com\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/bxta.com\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/#primaryimage","url":"https:\/\/bxta.com\/wp-content\/uploads\/2021\/05\/Screenshot-2021-05-06-at-16.38.44.png","contentUrl":"https:\/\/bxta.com\/wp-content\/uploads\/2021\/05\/Screenshot-2021-05-06-at-16.38.44.png","width":1106,"height":736},{"@type":"BreadcrumbList","@id":"https:\/\/bxta.com\/fr\/brachytherapy-alone-for-intermediate-risk-prostate-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bxta.com\/"},{"@type":"ListItem","position":2,"name":"Brachytherapy alone for intermediate-risk prostate cancer"}]},{"@type":"WebSite","@id":"https:\/\/bxta.com\/uk\/#website","url":"https:\/\/bxta.com\/uk\/","name":"BXTA","description":"Vamos combater juntos o cancro da pr\u00f3stata | BXTA","publisher":{"@id":"https:\/\/bxta.com\/uk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bxta.com\/uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Organization","@id":"https:\/\/bxta.com\/uk\/#organization","name":"BXTA","url":"https:\/\/bxta.com\/uk\/","logo":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/bxta.com\/uk\/#\/schema\/logo\/image\/","url":"https:\/\/bxta-staging.s3.eu-west-2.amazonaws.com\/app\/uploads\/2021\/09\/07212056\/BXTA-Logo.png","contentUrl":"https:\/\/bxta-staging.s3.eu-west-2.amazonaws.com\/app\/uploads\/2021\/09\/07212056\/BXTA-Logo.png","width":600,"height":373,"caption":"BXTA"},"image":{"@id":"https:\/\/bxta.com\/uk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/bxtainternational\/","https:\/\/x.com\/BXTA_","https:\/\/www.linkedin.com\/company\/bxtaccelyon","https:\/\/www.youtube.com\/channel\/UCkTU9L10CS5c1eWtGiMZ7gw"]},{"@type":"Person","@id":"https:\/\/bxta.com\/uk\/#\/schema\/person\/be7f4368cd4f7e11918870d00223473a","name":"Marketing BXTA","url":"https:\/\/bxta.com\/pt\/author\/marketingbxta\/"}]}},"_links":{"self":[{"href":"https:\/\/bxta.com\/pt\/wp-json\/wp\/v2\/posts\/2680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bxta.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bxta.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bxta.com\/pt\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/bxta.com\/pt\/wp-json\/wp\/v2\/comments?post=2680"}],"version-history":[{"count":2,"href":"https:\/\/bxta.com\/pt\/wp-json\/wp\/v2\/posts\/2680\/revisions"}],"predecessor-version":[{"id":2682,"href":"https:\/\/bxta.com\/pt\/wp-json\/wp\/v2\/posts\/2680\/revisions\/2682"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bxta.com\/pt\/wp-json\/wp\/v2\/media\/2642"}],"wp:attachment":[{"href":"https:\/\/bxta.com\/pt\/wp-json\/wp\/v2\/media?parent=2680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bxta.com\/pt\/wp-json\/wp\/v2\/categories?post=2680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bxta.com\/pt\/wp-json\/wp\/v2\/tags?post=2680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}